RAPT Therapeutics, Inc.
RAPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -60% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,550% | -1,789% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,490.4% | -1,814.9% |
| EPS Diluted | -25.488 | -24.372 | -20.611 | -20.213 |
| % Growth | -4.6% | -18.2% | -2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |